Our intestine harbors an incredible number of bacteria, the gut microbiota, encoding 150-fold more genes than our own genome. Each individual has his own personal and unique microbiota, with a large diversity between individuals. The contribution of the gut microbiota in health and diseases is undisputed, and recent studies demonstrated major alterations of the gut microbiota composition in patients with metabolic and inflammatory bowel diseases.

Management team is a blend of former executives of Fovea Pharmaceuticals (acquired by sanofi in 2009) and specialists of biomarkers.

Enterome’s technology was developed initially in a INRA laboratory by Dusko Ehrlich at Jouy-en-Josas, France.
Dr Ehrlich has developed the most advanced and clinically validated biomarker platform to establish quantitative description of gut microbiota and correlations with disease phenotypes. Breakthrough results have been published in numerous peer-reviewed journals, including two recent papers in Nature (2010 and 2011).
Dr. Ehrlich’s work has been supported by EU FP7 and industrial grants and most recent developments of this technology took place in the MetaHit consortium.

Enterome is advancing an internal pipeline of biomarkers in chronic serious diseases like NASH, type-2 diabetes, obesity and inflammatory bowel diseases (Crohn’s disease and ulcerative colitis).